QIAGEN announced that it has partnered with Genomics England to support the delivery of the Generation Study.
This first-of-its-kind initiative aims to sequence the genomes of 100,000 newborns in England to screen for over 200 selected conditions, enabling earlier diagnosis and treatment of rare conditions.
The study will identify conditions such as Metachromatic leukodystrophy (MLD) in babies sooner and could enable hundreds to benefit from earlier diagnosis and treatment that could help slow the progression of rare conditions and even extend their lives.
The QIAGEN Clinical Knowledge Base offers comprehensive genomic content built on expert manual curation. Rather than examining and interpreting each variant in real-time against the evidence found in the medical literature, newborn sequencing benefits greatly from pre-curated knowledge which is readily comparable to each newborn’s DNA.
For the Generation Study, QIAGEN curators provided comprehensive evidence for every variant seen across the 200 conditions included in the study.
